Thursday, July 23, 2026
Preview mode — showing bulk-ingested data not yet promoted to production. Hide preview

FDA · United States

fluticasone furoate — FDA regulatory status

fluticasone furoate (ARNUITY ELLIPTA) regulatory status in the United States is tracked from public FDA records and cross-linked clinical and patent datasets on NovaPharmaNews. Current status: FDA approved.

Status snapshot

Status
FDA approved
Brand
ARNUITY ELLIPTA
Originator
GlaxoSmithKline
Mechanism
Glucocorticoid receptor agonist
Target
Glucocorticoid receptor
Structured fields
7

Sponsor / originator context: GlaxoSmithKline. Pipeline programs and exclusivity signals below are joined from ClinicalTrials.gov-linked projects and USPTO/EPO patent rows associated with this INN.

Pharmacology context used for competitive intelligence: Glucocorticoid receptor agonist. Target: Glucocorticoid receptor. This page is a status aggregation for professional reference — not prescribing advice.

Regional decision snapshot — FDA: approved.

Linked evidence on this spoke: 8 published clinical programs and 0 related patent records. Use the tables below for NCT identifiers, phases, and exclusivity dates; verify against primary sources before BD or medical decisions.

Regulatory timeline

Regulator Region Status Date Source
FDA United States approved Evidence

Linked clinical programs

Related hubs

FAQ

What is the FDA approval status of fluticasone furoate?

fluticasone furoate currently shows FDA approved in our United States regulatory index. Confirm on the official FDA label or EPAR before clinical or commercial use.

Where does NovaPharmaNews get fluticasone furoate regulatory data?

Status fields are joined from public sources (openFDA / EMA / regional agencies), ClinicalTrials.gov-linked programs, and patent registries. See /about/data-sources for attribution.

How many clinical programs are linked to fluticasone furoate?

This spoke lists 8 published programs associated with fluticasone furoate in our pipeline index.